sVAP-1: a novel potential therapeutic target and marker for risk stratification in primary sclerosing cholangitis

Primary sclerosing cholangitis (PSC) is a chronic condition affecting the liver, targeting mainly intra- and extra-hepatic biliary ducts, potentially able to evolve to cirrhosis, biliary cancer and liver failure (1). Lack of understanding of its pathogenesis is likely to be one of the main reasons why there is still no effective treatment besides liver transplantation.